{"id":476782,"date":"2021-04-15T08:03:46","date_gmt":"2021-04-15T12:03:46","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/revolo-biotherapeutics-enters-manufacturing-agreement-with-cordenpharma-to-scale-up-and-manufacture-1104-for-the-treatment-of-eosinophilic-esophagitis-and-allergic-disease\/"},"modified":"2021-04-15T08:03:46","modified_gmt":"2021-04-15T12:03:46","slug":"revolo-biotherapeutics-enters-manufacturing-agreement-with-cordenpharma-to-scale-up-and-manufacture-1104-for-the-treatment-of-eosinophilic-esophagitis-and-allergic-disease","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/revolo-biotherapeutics-enters-manufacturing-agreement-with-cordenpharma-to-scale-up-and-manufacture-1104-for-the-treatment-of-eosinophilic-esophagitis-and-allergic-disease\/","title":{"rendered":"Revolo Biotherapeutics Enters Manufacturing Agreement with CordenPharma to Scale Up and Manufacture \u20181104 for the Treatment of Eosinophilic Esophagitis and Allergic Disease"},"content":{"rendered":"

\nAgreement ensures supply to support clinical and commercial operations
\n<\/h2>\n
\n

NEW ORLEANS and LONDON, April 15, 2021 (GLOBE NEWSWIRE) — Revolo Biotherapeutics (\u201cRevolo Bio\u201d or the \u201cCompany\u201d), a Company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, announced today that it has entered into a Master Service Agreement with a Contract Development & Manufacturing Organization (CDMO), CordenPharma, for the production of Revolo Bio\u2019s first-in-class peptide and immune system resetting drug product, \u20181104, to support upcoming Phase 2 clinical trials in patients with eosinophilic esophagitis (EoE) and allergic disease. CordenPharma is fully equipped to manufacture peptide Active Pharmaceutical Ingredients (APIs) for the clinical supplies of future studies and to serve as an ongoing commercial supply partner.<\/p>\n

\u201cCordenPharma is a world leader in the development, scale-up and manufacturing of chemically synthesized APIs, making it an ideal manufacturing partner for \u20181104,\u201d said Jonathan Rigby, Group Chief Executive Officer of Revolo Bio. \u201cWith this partnership, we are ready to ramp-up and scale-up manufacturing to support our two upcoming Phase 2 trials, which we plan to initiate before the end of 2021. We look forward to further evaluating \u20181104\u2019s ability to reset the immune system to potentially provide patients with a revolutionary treatment option that achieves long-term disease remission without immune system suppression.\u201d<\/p>\n

CordenPharma Chief Executive Officer Dr. Michael Quirmbach commented, \u201cThe CordenPharma team is looking forward to growing this ongoing commercial supply partnership with Revolo Bio, starting with the manufacture of peptide APIs for their upcoming clinical trials. We are hopeful these important studies will lead to critical life-saving medications for their patients.\u201d<\/p>\n

Under the terms of the agreement, CordenPharma will manufacture \u20181104 following Current Good Manufacturing Practices (cGMP) at its facility in Boulder, Colorado.<\/p>\n

\n About CordenPharma<\/strong>
\n
CordenPharma, the global pharmaceutical service & manufacturing platform of International Chemical Investors Group (ICIG), is a full-service partner in the Contract Development & Manufacturing (CDMO) of APIs, Drug Products, and associated Packaging Services. Through a growing network of cGMP facilities across Europe and the US organized under four Technology Platforms \u2013 Peptides, Lipids & Carbohydrates, Injectables, Highly Potent & Oncology, and Small Molecules \u2013 CordenPharma experts translate complex processes and projects at any stage of development into high-value products.<\/p>\n

\n About Revolo Biotherapeutics <\/strong>
\n
Revolo Biotherapeutics is developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic disease, without the immune system suppression seen with current therapies. Its two drug candidates, \u20181805 and \u20181104, a protein and a peptide respectively, reset the immune system by preventing the chronic pro-inflammatory immune response that results in autoimmune or allergic disease. \u20181805 is a modified analogue of a key protein in immune function and is entering clinical development for moderate-to-severe rheumatoid arthritis and non-infectious uveitis. \u20181104 is a peptide derived from a natural immune-regulatory protein and is entering clinical development for patients with eosinophilic esophagitis (EoE) and allergic disease. The disease-agnostic mechanism of action of Revolo Biotherapeutic\u2019s assets provides a potential platform for the development of treatments for multiple autoimmune and allergic diseases.<\/p>\n

For further information, please visit www.revolobio.com<\/a>.<\/p>\n

\n Company Contact<\/strong>
\n
Marylyn Rigby, VP Investor Relations & Marketing
marylyn.rigby@revolobio.com<\/p>\n

\n Media Contact <\/strong>
\n
Monica Rouco Molina, Ph.D.
LifeSci Communications
+1-929-469-3850
mroucomolina@lifescicomms.com<\/a><\/p>\n

\u00a0<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Agreement ensures supply to support clinical and commercial operations NEW ORLEANS and LONDON, April 15, 2021 (GLOBE NEWSWIRE) — Revolo Biotherapeutics (\u201cRevolo Bio\u201d or the \u201cCompany\u201d), a Company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, announced today that it has entered into a Master Service Agreement with a Contract Development & Manufacturing Organization (CDMO), CordenPharma, for the production of Revolo Bio\u2019s first-in-class peptide and immune system resetting drug product, \u20181104, to support upcoming Phase 2 clinical trials in patients with eosinophilic esophagitis (EoE) and allergic disease. CordenPharma is fully equipped to manufacture peptide Active Pharmaceutical Ingredients (APIs) for the clinical supplies of future studies and to serve as … <\/p>\n

Continue reading “Revolo Biotherapeutics Enters Manufacturing Agreement with CordenPharma to Scale Up and Manufacture \u20181104 for the Treatment of Eosinophilic Esophagitis and Allergic Disease”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-476782","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nRevolo Biotherapeutics Enters Manufacturing Agreement with CordenPharma to Scale Up and Manufacture \u20181104 for the Treatment of Eosinophilic Esophagitis and Allergic Disease - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/revolo-biotherapeutics-enters-manufacturing-agreement-with-cordenpharma-to-scale-up-and-manufacture-1104-for-the-treatment-of-eosinophilic-esophagitis-and-allergic-disease\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Revolo Biotherapeutics Enters Manufacturing Agreement with CordenPharma to Scale Up and Manufacture \u20181104 for the Treatment of Eosinophilic Esophagitis and Allergic Disease - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Agreement ensures supply to support clinical and commercial operations NEW ORLEANS and LONDON, April 15, 2021 (GLOBE NEWSWIRE) — Revolo Biotherapeutics (\u201cRevolo Bio\u201d or the \u201cCompany\u201d), a Company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, announced today that it has entered into a Master Service Agreement with a Contract Development & Manufacturing Organization (CDMO), CordenPharma, for the production of Revolo Bio\u2019s first-in-class peptide and immune system resetting drug product, \u20181104, to support upcoming Phase 2 clinical trials in patients with eosinophilic esophagitis (EoE) and allergic disease. CordenPharma is fully equipped to manufacture peptide Active Pharmaceutical Ingredients (APIs) for the clinical supplies of future studies and to serve as … Continue reading "Revolo Biotherapeutics Enters Manufacturing Agreement with CordenPharma to Scale Up and Manufacture \u20181104 for the Treatment of Eosinophilic Esophagitis and Allergic Disease"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/revolo-biotherapeutics-enters-manufacturing-agreement-with-cordenpharma-to-scale-up-and-manufacture-1104-for-the-treatment-of-eosinophilic-esophagitis-and-allergic-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-15T12:03:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxNzI4MSM0MTIxOTE3IzUwMDA3NjgyNQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolo-biotherapeutics-enters-manufacturing-agreement-with-cordenpharma-to-scale-up-and-manufacture-1104-for-the-treatment-of-eosinophilic-esophagitis-and-allergic-disease\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolo-biotherapeutics-enters-manufacturing-agreement-with-cordenpharma-to-scale-up-and-manufacture-1104-for-the-treatment-of-eosinophilic-esophagitis-and-allergic-disease\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Revolo Biotherapeutics Enters Manufacturing Agreement with CordenPharma to Scale Up and Manufacture \u20181104 for the Treatment of Eosinophilic Esophagitis and Allergic Disease\",\"datePublished\":\"2021-04-15T12:03:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolo-biotherapeutics-enters-manufacturing-agreement-with-cordenpharma-to-scale-up-and-manufacture-1104-for-the-treatment-of-eosinophilic-esophagitis-and-allergic-disease\\\/\"},\"wordCount\":554,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolo-biotherapeutics-enters-manufacturing-agreement-with-cordenpharma-to-scale-up-and-manufacture-1104-for-the-treatment-of-eosinophilic-esophagitis-and-allergic-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxNzI4MSM0MTIxOTE3IzUwMDA3NjgyNQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolo-biotherapeutics-enters-manufacturing-agreement-with-cordenpharma-to-scale-up-and-manufacture-1104-for-the-treatment-of-eosinophilic-esophagitis-and-allergic-disease\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolo-biotherapeutics-enters-manufacturing-agreement-with-cordenpharma-to-scale-up-and-manufacture-1104-for-the-treatment-of-eosinophilic-esophagitis-and-allergic-disease\\\/\",\"name\":\"Revolo Biotherapeutics Enters Manufacturing Agreement with CordenPharma to Scale Up and Manufacture \u20181104 for the Treatment of Eosinophilic Esophagitis and Allergic Disease - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolo-biotherapeutics-enters-manufacturing-agreement-with-cordenpharma-to-scale-up-and-manufacture-1104-for-the-treatment-of-eosinophilic-esophagitis-and-allergic-disease\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolo-biotherapeutics-enters-manufacturing-agreement-with-cordenpharma-to-scale-up-and-manufacture-1104-for-the-treatment-of-eosinophilic-esophagitis-and-allergic-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxNzI4MSM0MTIxOTE3IzUwMDA3NjgyNQ==\",\"datePublished\":\"2021-04-15T12:03:46+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolo-biotherapeutics-enters-manufacturing-agreement-with-cordenpharma-to-scale-up-and-manufacture-1104-for-the-treatment-of-eosinophilic-esophagitis-and-allergic-disease\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolo-biotherapeutics-enters-manufacturing-agreement-with-cordenpharma-to-scale-up-and-manufacture-1104-for-the-treatment-of-eosinophilic-esophagitis-and-allergic-disease\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolo-biotherapeutics-enters-manufacturing-agreement-with-cordenpharma-to-scale-up-and-manufacture-1104-for-the-treatment-of-eosinophilic-esophagitis-and-allergic-disease\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxNzI4MSM0MTIxOTE3IzUwMDA3NjgyNQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxNzI4MSM0MTIxOTE3IzUwMDA3NjgyNQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolo-biotherapeutics-enters-manufacturing-agreement-with-cordenpharma-to-scale-up-and-manufacture-1104-for-the-treatment-of-eosinophilic-esophagitis-and-allergic-disease\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Revolo Biotherapeutics Enters Manufacturing Agreement with CordenPharma to Scale Up and Manufacture \u20181104 for the Treatment of Eosinophilic Esophagitis and Allergic Disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Revolo Biotherapeutics Enters Manufacturing Agreement with CordenPharma to Scale Up and Manufacture \u20181104 for the Treatment of Eosinophilic Esophagitis and Allergic Disease - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/revolo-biotherapeutics-enters-manufacturing-agreement-with-cordenpharma-to-scale-up-and-manufacture-1104-for-the-treatment-of-eosinophilic-esophagitis-and-allergic-disease\/","og_locale":"en_US","og_type":"article","og_title":"Revolo Biotherapeutics Enters Manufacturing Agreement with CordenPharma to Scale Up and Manufacture \u20181104 for the Treatment of Eosinophilic Esophagitis and Allergic Disease - Market Newsdesk","og_description":"Agreement ensures supply to support clinical and commercial operations NEW ORLEANS and LONDON, April 15, 2021 (GLOBE NEWSWIRE) — Revolo Biotherapeutics (\u201cRevolo Bio\u201d or the \u201cCompany\u201d), a Company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, announced today that it has entered into a Master Service Agreement with a Contract Development & Manufacturing Organization (CDMO), CordenPharma, for the production of Revolo Bio\u2019s first-in-class peptide and immune system resetting drug product, \u20181104, to support upcoming Phase 2 clinical trials in patients with eosinophilic esophagitis (EoE) and allergic disease. CordenPharma is fully equipped to manufacture peptide Active Pharmaceutical Ingredients (APIs) for the clinical supplies of future studies and to serve as … Continue reading \"Revolo Biotherapeutics Enters Manufacturing Agreement with CordenPharma to Scale Up and Manufacture \u20181104 for the Treatment of Eosinophilic Esophagitis and Allergic Disease\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/revolo-biotherapeutics-enters-manufacturing-agreement-with-cordenpharma-to-scale-up-and-manufacture-1104-for-the-treatment-of-eosinophilic-esophagitis-and-allergic-disease\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-15T12:03:46+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxNzI4MSM0MTIxOTE3IzUwMDA3NjgyNQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolo-biotherapeutics-enters-manufacturing-agreement-with-cordenpharma-to-scale-up-and-manufacture-1104-for-the-treatment-of-eosinophilic-esophagitis-and-allergic-disease\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolo-biotherapeutics-enters-manufacturing-agreement-with-cordenpharma-to-scale-up-and-manufacture-1104-for-the-treatment-of-eosinophilic-esophagitis-and-allergic-disease\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Revolo Biotherapeutics Enters Manufacturing Agreement with CordenPharma to Scale Up and Manufacture \u20181104 for the Treatment of Eosinophilic Esophagitis and Allergic Disease","datePublished":"2021-04-15T12:03:46+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolo-biotherapeutics-enters-manufacturing-agreement-with-cordenpharma-to-scale-up-and-manufacture-1104-for-the-treatment-of-eosinophilic-esophagitis-and-allergic-disease\/"},"wordCount":554,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolo-biotherapeutics-enters-manufacturing-agreement-with-cordenpharma-to-scale-up-and-manufacture-1104-for-the-treatment-of-eosinophilic-esophagitis-and-allergic-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxNzI4MSM0MTIxOTE3IzUwMDA3NjgyNQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolo-biotherapeutics-enters-manufacturing-agreement-with-cordenpharma-to-scale-up-and-manufacture-1104-for-the-treatment-of-eosinophilic-esophagitis-and-allergic-disease\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/revolo-biotherapeutics-enters-manufacturing-agreement-with-cordenpharma-to-scale-up-and-manufacture-1104-for-the-treatment-of-eosinophilic-esophagitis-and-allergic-disease\/","name":"Revolo Biotherapeutics Enters Manufacturing Agreement with CordenPharma to Scale Up and Manufacture \u20181104 for the Treatment of Eosinophilic Esophagitis and Allergic Disease - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolo-biotherapeutics-enters-manufacturing-agreement-with-cordenpharma-to-scale-up-and-manufacture-1104-for-the-treatment-of-eosinophilic-esophagitis-and-allergic-disease\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolo-biotherapeutics-enters-manufacturing-agreement-with-cordenpharma-to-scale-up-and-manufacture-1104-for-the-treatment-of-eosinophilic-esophagitis-and-allergic-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxNzI4MSM0MTIxOTE3IzUwMDA3NjgyNQ==","datePublished":"2021-04-15T12:03:46+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolo-biotherapeutics-enters-manufacturing-agreement-with-cordenpharma-to-scale-up-and-manufacture-1104-for-the-treatment-of-eosinophilic-esophagitis-and-allergic-disease\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/revolo-biotherapeutics-enters-manufacturing-agreement-with-cordenpharma-to-scale-up-and-manufacture-1104-for-the-treatment-of-eosinophilic-esophagitis-and-allergic-disease\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolo-biotherapeutics-enters-manufacturing-agreement-with-cordenpharma-to-scale-up-and-manufacture-1104-for-the-treatment-of-eosinophilic-esophagitis-and-allergic-disease\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxNzI4MSM0MTIxOTE3IzUwMDA3NjgyNQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxNzI4MSM0MTIxOTE3IzUwMDA3NjgyNQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolo-biotherapeutics-enters-manufacturing-agreement-with-cordenpharma-to-scale-up-and-manufacture-1104-for-the-treatment-of-eosinophilic-esophagitis-and-allergic-disease\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Revolo Biotherapeutics Enters Manufacturing Agreement with CordenPharma to Scale Up and Manufacture \u20181104 for the Treatment of Eosinophilic Esophagitis and Allergic Disease"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/476782","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=476782"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/476782\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=476782"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=476782"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=476782"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}